Cilostazol in Parkinson's Disease

Launched by AIN SHAMS UNIVERSITY · Sep 22, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a medication called Cilostazol to see if it can help people with Parkinson's disease. Parkinson's is a condition that affects movement and is currently managed with medications that can ease symptoms but do not stop the disease from getting worse. Researchers believe that Cilostazol may have special properties that could protect brain cells and reduce inflammation, which are both important factors in the progression of Parkinson's disease. By participating in this trial, individuals may have the chance to contribute to important research that could lead to better treatments for Parkinson’s.

To be eligible for the trial, participants must be adults who have been diagnosed with Parkinson's disease for at least five years and have been on a stable medication called Levodopa/Carbidopa for the past six months. They should also have experienced some movement difficulties known as dyskinesia. It's important to note that people with certain conditions, such as severe liver or kidney problems, or those taking specific blood thinners, cannot participate. The trial is not yet recruiting participants, but it aims to explore how Cilostazol could improve the health and well-being of those living with Parkinson's disease.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • -Adult patients.
• • Both males and females will be included
• • Diagnosed Parkinson's disease according to the MDS criteria 2015
• • At least 5 years of disease duration
• • On stable Levodopa\\carbidopa regimen for the past 6 months.
• • Clinically diagnosed with dyskinesia
• Exclusion Criteria:
• • -Secondary causes of Parkinsonism
• • Atypical parkinsonian syndromes
• • Active malignancy
• • Known intolerance or hypersensitivity to cilostazol
• • Participation in other interventional trials
• • Patients with hepatic (AST and ALT more than 3 times the upper normal limit) or renal impairment (eGFR less than 60 ml\\min).
• • Patients receiving warfarin, other anti-coagulants or anti-platelet therapy.
• • Patients with Congestive heart failure.